Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sarah D. Luppino
Observed name:
Sarah Luppino
Institutions:
Harvard University,
Massachusetts General Hospital
Observed institutions:
Harvard University,
University of Massachusetts Chan Medical School,
Massachusetts General Hospital,
UMass Memorial Medical Center
ORCID:
0009-0009-1689-6642
Observed ORCID:
0009-0009-1689-6642
OpenAlex ID:
A5077675538
SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS
2020
·
Christian Mueller
, James D. Berry
, et al.
·
New England Journal of Medicine
·
263
PDF
Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines
2022
·
Emily G. Baxi
, Terri Thompson
, et al.
·
Nature Neuroscience
·
157
PDF
Identifying patterns in amyotrophic lateral sclerosis progression from sparse longitudinal data
2022
·
Divya Ramamoorthy
, Kristen Severson
, et al.
·
Nature Computational Science
·
60
PDF
Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis
2026
·
Timothy M. Miller
, Merit E. Cudkowicz
, et al.
·
JAMA Neurology
·
40
PDF
A pilot trial of RNS60 in amyotrophic lateral sclerosis
2018
·
Sabrina Paganoni
, Mohamad J. Alshikho
, et al.
·
Muscle & Nerve
·
37
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis
2025
·
Sabrina Paganoni
, Christina N. Fournier
, et al.
·
JAMA Network Open
·
26
Pridopidine in Amyotrophic Lateral Sclerosis
2025
·
Douglas Hayden
, Po-Ying Lai
, et al.
·
JAMA
·
21
Safety and activity of anti‐CD14 antibody IC14 (atibuclimab) in ALS : Experience with expanded access protocol
2022
·
Dario Gelevski
, Grace Addy
, et al.
·
Muscle & Nerve
·
21
PDF
An expanded access protocol of RT001 in amyotrophic lateral sclerosis—Initial experience with a lipid peroxidation inhibitor
2022
·
Megan Yerton
, Allison Winter
, et al.
·
Muscle & Nerve
·
21
Verdiperstat in Amyotrophic Lateral Sclerosis
2025
·
Douglas * deceased Hayden
, Po-Ying Lai
, et al.
·
JAMA Neurology
·
17
PDF
CNM-Au8 in Amyotrophic Lateral Sclerosis
2025
·
Douglas Hayden
, Po-Ying Lai
, et al.
·
JAMA
·
17
Disease related changes in ATAC-seq of iPSC-derived motor neuron lines from ALS patients and controls
2024
·
Stanislav Tsitkov
, Kelsey Valentine
, et al.
·
Nature Communications
·
15
PDF
Multicenter expanded access program for access to investigational products for amyotrophic lateral sclerosis
2024
·
Dylan V. Neel
, Clara Baselga‐Garriga
, et al.
·
Muscle & Nerve
·
10
Expanded access protocol ( EAP ) program for access to investigational products for amyotrophic lateral sclerosis ( ALS )
2023
·
Megan Yerton
, Allison Winter
, et al.
·
Muscle & Nerve
·
6
PDF
An Expanded Access Protocol of RNS60 in Amyotrophic Lateral Sclerosis
2025
·
Grace Addy
, Erica Scirocco
, et al.
·
Muscle & Nerve
·
3
Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
2026
·
Merit E Cudkowicz
, Merit E Cudkowicz
, et al.
·
The Lancet Neurology
·
1
Amyotrophic Lateral Sclerosis Clinical Research Site Operations: Emerging Challenges and Potential Solutions From Multiple Sites in the US
2025
·
Erica Scirocco
, Sarah D. Luppino
, et al.
·
Muscle & Nerve
·
1
PDF
NeuroREACH™ Platform for Expanded Access Program (EAP) Trials as the Foundation for Clinical Research of the Future (5463)
2020
·
Alexander Sherman
, Amanda Podesta
, et al.
·
Neurology
·
1
Optimizing Research Operations and Resource Utilization in ALS Care: Insights From the Tofersen Antisense Oligonucleotide Expanded Access Protocol
2026
·
Alison Wheeler
, Kush Mehta
, et al.
·
Muscle & Nerve
Show more works
View as search
Works count:
19
Citation count:
715
H-index:
12
I10-index:
13
Year
Topic
Type
